RU2739036C2 - Метод - Google Patents

Метод Download PDF

Info

Publication number
RU2739036C2
RU2739036C2 RU2018112516A RU2018112516A RU2739036C2 RU 2739036 C2 RU2739036 C2 RU 2739036C2 RU 2018112516 A RU2018112516 A RU 2018112516A RU 2018112516 A RU2018112516 A RU 2018112516A RU 2739036 C2 RU2739036 C2 RU 2739036C2
Authority
RU
Russia
Prior art keywords
individual
neoantigens
clonal
immune
cancer
Prior art date
Application number
RU2018112516A
Other languages
English (en)
Russian (ru)
Other versions
RU2018112516A (ru
RU2018112516A3 (enExample
Inventor
Николас МАКГРАНАХАН
Рэйчел РОЗЕНТАЛЬ
Чарльз СВОНТОН
Карл ПЕГГЗ
Серхио КЕСАДА
Original Assignee
Кэнсэр Ресерч Текнолоджи Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кэнсэр Ресерч Текнолоджи Лимитед filed Critical Кэнсэр Ресерч Текнолоджи Лимитед
Publication of RU2018112516A publication Critical patent/RU2018112516A/ru
Publication of RU2018112516A3 publication Critical patent/RU2018112516A3/ru
Application granted granted Critical
Publication of RU2739036C2 publication Critical patent/RU2739036C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
RU2018112516A 2015-09-10 2016-09-12 Метод RU2739036C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1516047.6 2015-09-10
GBGB1516047.6A GB201516047D0 (en) 2015-09-10 2015-09-10 Method
PCT/EP2016/071471 WO2017042394A1 (en) 2015-09-10 2016-09-12 "immune checkpoint intervention" in cancer

Publications (3)

Publication Number Publication Date
RU2018112516A RU2018112516A (ru) 2019-10-10
RU2018112516A3 RU2018112516A3 (enExample) 2020-02-10
RU2739036C2 true RU2739036C2 (ru) 2020-12-21

Family

ID=54362973

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018112516A RU2739036C2 (ru) 2015-09-10 2016-09-12 Метод

Country Status (11)

Country Link
US (1) US11098121B2 (enExample)
EP (1) EP3347039B1 (enExample)
JP (1) JP7073254B2 (enExample)
KR (1) KR20180081490A (enExample)
CN (2) CN120624654A (enExample)
AU (1) AU2016319316B2 (enExample)
BR (1) BR112018004878B1 (enExample)
CA (1) CA2997651A1 (enExample)
GB (1) GB201516047D0 (enExample)
RU (1) RU2739036C2 (enExample)
WO (1) WO2017042394A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
EP2854057B1 (en) 2010-05-18 2018-03-07 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
JP6153874B2 (ja) 2011-02-09 2017-06-28 ナテラ， インコーポレイテッド 非侵襲的出生前倍数性呼び出しのための方法
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
AU2015249846B2 (en) 2014-04-21 2021-07-22 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
JP7305300B2 (ja) 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
EP3603665B1 (en) * 2015-04-27 2025-12-31 Cancer Research Technology Limited Personalized T-cell production methods for cancer treatment
EP3294906B1 (en) 2015-05-11 2024-07-10 Natera, Inc. Methods for determining ploidy
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
WO2017181202A2 (en) 2016-04-15 2017-10-19 Natera, Inc. Methods for lung cancer detection
WO2018067517A1 (en) 2016-10-04 2018-04-12 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) * 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
WO2018136664A1 (en) * 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
CN110799196B (zh) * 2017-03-31 2024-02-13 行动基因(智财)有限公司 致免疫性的癌症特异抗原决定位的排名系统
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
JP7307048B2 (ja) 2017-07-14 2023-07-11 ザ フランシス クリック インスティチュート リミティッド 腫瘍におけるｈｌａアレルの分析及びそれらの使用
WO2019016174A1 (en) * 2017-07-18 2019-01-24 Institut Gustave Roussy METHOD FOR ASSESSING RESPONSE TO TARGETING DRUG PD-1 / PDL-1 MEDICINES
JP7072825B2 (ja) * 2017-09-13 2022-05-23 三菱電機ソフトウエア株式会社 コピー数計測装置、コピー数計測プログラムおよびコピー数計測方法
USD844652S1 (en) * 2017-11-26 2019-04-02 Jan Magnus Edman Display screen with graphical user interface
KR102805731B1 (ko) * 2017-12-01 2025-06-19 일루미나, 인코포레이티드 체성 돌연변이 클론형성능을 결정하기 위한 방법 및 시스템
WO2019118926A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
CA3090426A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US20220177534A1 (en) * 2018-05-10 2022-06-09 The Regents Of The University Of California Ccl21 and checkpoint inhibitors for the treatment of cancer
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
US11427873B2 (en) 2018-08-10 2022-08-30 Omniseq, Inc. Methods and systems for assessing proliferative potential and resistance to immune checkpoint blockade
JP2022515416A (ja) * 2018-12-21 2022-02-18 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 免疫チェックポイント阻害療法からの利益を予測する方法
CN111383713B (zh) * 2018-12-29 2023-08-01 北京安诺优达医学检验实验室有限公司 ctDNA检测分析装置及方法
JP2022523672A (ja) * 2019-01-28 2022-04-26 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム がんを治療するための金属キレート化剤併用療法
EP3947737A2 (en) * 2019-04-02 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
WO2020218322A1 (ja) * 2019-04-23 2020-10-29 国立大学法人東北大学 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
EP3980559A1 (en) 2019-06-06 2022-04-13 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
CN111394454B (zh) * 2020-01-06 2023-03-14 江苏省肿瘤防治研究所（江苏省肿瘤医院） 一种免疫相关生物标志物及其在头颈部鳞状细胞癌预后诊断中的应用
JP7617574B2 (ja) * 2020-01-07 2025-01-20 コリア アドバンスド インスティテュート オブ サイエンス アンド テクノロジー 新生抗原をスクリーニングする方法、システム及びその用途
WO2021142088A1 (en) * 2020-01-07 2021-07-15 The Trustees Of The University Of Pennsylvania Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies
EP3868897A1 (en) * 2020-02-20 2021-08-25 Worldwide Innovative Network Method for improving the treatment with immune checkpoint blockade therapy
WO2022074648A1 (en) * 2020-10-05 2022-04-14 4C Biomed Limited Marker for response to pd-1/pd-l1 immunotherapy
CN112735513B (zh) * 2021-01-04 2021-11-19 江苏先声医疗器械有限公司 基于dna甲基化谱的肿瘤免疫检查点抑制剂治疗有效性评估模型的构建方法
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
CN117881794A (zh) * 2021-06-30 2024-04-12 诺瓦瑟拉姆株式会社 制备包含血中循环肿瘤细胞的试样的方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988000344A1 (en) 1986-07-03 1988-01-14 Bio-Rad Laboratories, Inc. Peptide fragments of organ-specific neoantigens
US5670325A (en) * 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
JP5690272B2 (ja) 2008-11-03 2015-03-25 ステフティン サンクイン ブルードフォルツィーニング サンプル中の抗原応答性細胞の検出
WO2010144192A1 (en) 2009-05-05 2010-12-16 Children's Medical Center Corporation Prognosis indicators for solid human tumors
US8176660B2 (en) 2009-07-30 2012-05-15 Nike, Inc. Customizable stud for an article of footwear
PL2482849T3 (pl) 2009-09-30 2018-11-30 Memorial Sloan-Kettering Cancer Center Skojarzona immunoterapia w leczeniu nowotworu
LT3892295T (lt) 2011-05-24 2023-07-10 BioNTech SE Individualizuotos vakcinos nuo vėžio
EP2872653B1 (en) 2012-07-12 2019-03-13 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
WO2014026096A1 (en) 2012-08-10 2014-02-13 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
DK2904111T3 (en) 2012-10-01 2018-03-12 Adaptive Biotechnologies Corp Immune competence evaluation of adaptive immune receptor diversity and clonality characterization
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
BR112015025460B1 (pt) 2013-04-07 2024-01-02 The Broad Institute, Inc. Método para a produção de uma vacina personalizada contra a neoplasia para um indivíduo diagnosticado como tendo uma neoplasia, vacina personalizada e uso da mesma
CA2919567A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
WO2015014375A1 (en) 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
CA2932798C (en) 2013-12-06 2022-09-20 The Broad Institute, Inc. Formulations for neoplasia vaccines
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
AU2015346295A1 (en) 2014-11-13 2017-05-25 The Johns Hopkins University Checkpoint blockade and microsatellite instability
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
MX393750B (es) 2014-12-31 2025-03-24 Checkmate Pharmaceuticals Inc Inmunoterapia antitumoral combinada.
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
MY190083A (en) 2015-03-17 2022-03-25 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
ES2811345T3 (es) 2015-03-23 2021-03-11 Jounce Therapeutics Inc Anticuerpos contra ICOS
EP3603665B1 (en) 2015-04-27 2025-12-31 Cancer Research Technology Limited Personalized T-cell production methods for cancer treatment
CN108351916A (zh) 2015-07-14 2018-07-31 个人基因组诊断公司 新生抗原分析
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
EP3383422B1 (en) 2015-12-02 2021-08-11 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
JP2019505579A (ja) 2015-12-23 2019-02-28 ムーンショット ファーマ エルエルシー 免疫応答を誘導するための方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011143656A2 (en) * 2010-05-14 2011-11-17 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
WO2015103037A2 (en) * 2014-01-02 2015-07-09 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
N. MCGRANAHAN ET AL, "Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade", SCIENCE (AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE), WASHINGTON DC USA, (20160325), vol. 351, no. 6280, doi:10.1126/science.aaf1490, ISSN 0036-8075, pages 1463 - 1469. VAN ROOIJ et al., "Tumor exome analysis reveals neoantigen-specific T- cell reactivity in an ipilimumab-responsive melanoma", J Clin Oncol., (20130916), vol. 31, pages e439 - e442. *

Also Published As

Publication number Publication date
RU2018112516A (ru) 2019-10-10
US20180251553A1 (en) 2018-09-06
KR20180081490A (ko) 2018-07-16
AU2016319316A1 (en) 2018-02-22
RU2018112516A3 (enExample) 2020-02-10
CA2997651A1 (en) 2017-03-16
WO2017042394A1 (en) 2017-03-16
CN108135985A (zh) 2018-06-08
EP3347039A1 (en) 2018-07-18
JP2018527935A (ja) 2018-09-27
EP3347039B1 (en) 2021-08-11
US11098121B2 (en) 2021-08-24
BR112018004878B1 (pt) 2022-07-05
CN120624654A (zh) 2025-09-12
BR112018004878A2 (enExample) 2018-10-02
AU2016319316B2 (en) 2022-09-08
JP7073254B2 (ja) 2022-05-23
GB201516047D0 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
RU2739036C2 (ru) Метод
Clarke et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Ozato et al. Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer
Braun et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
Harel et al. Proteomics of melanoma response to immunotherapy reveals mitochondrial dependence
Gettinger et al. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
Gruosso et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers
Havel et al. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Lowery et al. Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
Guo et al. Phenotyping of immune and endometrial epithelial cells in endometrial carcinomas revealed by single-cell RNA sequencing
US11644467B2 (en) Prediction of response to immune-modulatory therapies
Blanco-Heredia et al. Converging and evolving immuno-genomic routes toward immune escape in breast cancer
Takei et al. Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma
Willemsen et al. Changes in AXL and/or MITF melanoma subpopulations in patients receiving immunotherapy
Køllgaard et al. Pre-vaccination frequencies of Th17 cells correlate with vaccine-induced T-cell responses to survivin-derived peptide epitopes
Ibáñez-Molero et al. Tumour-reactive heterotypic CD8 T cell clusters from clinical samples
Mathieson et al. Subpopulations of cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer are a predictor of poor clinical outcome
Schwarz et al. Peptide-stimulated T cells bypass immune checkpoint inhibitor resistance and eliminate autologous microsatellite instable colorectal cancer cells
Daley et al. SARC028 samples reveal an interplay between TGF-beta, interferon signaling and low HLA class I expression as contributors to Ewing sarcoma checkpoint blockade resistance
HK1255677A1 (en) Immune checkpoint intervention in cancer
HK1255677B (en) Immune checkpoint intervention in cancer
Mohebalizadeh et al. Biomarkers for Monitoring the Immunotherapy Response to Cancer
Jonsson et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma
Garrido-Barros et al. Immune Checkpoint Blockade Response Biomarkers